FindMyKOL
Clinical trialNCT04592861TerminatedPhase 3Interventional

Carbon Ion RT for Locally Advanced Pancreatic Cancer

NCT04592861 is a phase 3 interventional trial sponsored by Albert Einstein College of Medicine. As of 21 Nov 2026, it was terminated. It studies Chemotherapy drug in Pancreatic Cancer. The registry lists an enrollment of 5 participants at 1 site in 1 country. The registry lists a start date of 1 Nov 2020 and a primary completion date of 24 Aug 2022. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04592861
FieldValue
Registry IDNCT04592861
StatusTerminated
PhasePhase 3
Study typeInterventional trial
Lead sponsorAlbert Einstein College of Medicine
Enrollment5
Registered sites1
Countries1
ConditionsPancreatic Cancer
DrugsChemotherapy drug
Start1 Nov 2020
Primary completion24 Aug 2022
Study completion24 Aug 2022
Last update posted5 Jan 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label randomized trial. Subjects will be randomized in a 2:1 ratio to receive carbon ion radiotherapy versus standard care for locally advanced pancreatic cancer. Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians. Subjects on the control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon ion radiotherapy) if disease progression occurs.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site
  • Shanghai Proton and Heavy Ion Center (sphic)

    Shanghai, Shanghai Municipality

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Chemotherapy drug
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04592861

Each answer restates registry values shown on this page.

What is NCT04592861?

NCT04592861 is a phase 3 interventional trial sponsored by Albert Einstein College of Medicine. It studies Chemotherapy drug in Pancreatic Cancer.

Who leads NCT04592861?

The registry names Nitin Ohri, MD (principal investigator, Associate Professor) as the overall official.

Where does NCT04592861 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT04592861 study?

The registered drug and biological interventions are Chemotherapy drug.

When did NCT04592861 end?

The registry lists a primary completion date of 24 Aug 2022 and a study completion date of 24 Aug 2022. The sponsor last updated the record on 5 Jan 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.